Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 760 participants.

Also called NCT01870804

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 760 participants (enrolled count) (from the registry)
Sponsor
Centro Cardiopatici Toscani (from the registry)
Registry
  • NCT NCT01870804
Other papers using this trial's data
  • A Prospective, Randomized, Open-Label Trial of Atorvastatin versus Rosuvastatin in the Prevention of Contrast-Induced Acute Kidney Injury, Worsened Renal Function at 30 Days, and Clinical Events After Acute Coronary Angiography: the PRATO-ACS-2 Study Cardiorenal medicine, 2020 DOI, PubMed 32434204

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01870804. Randomized; double masking; primary purpose prevention. Start 2013-05 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)
Acronym
PRATO-ACS-2
Condition
Acute Coronary Syndrome
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Atorvastatin
Lead sponsor
Centro Cardiopatici Toscani (class: other)

Record details

Record id
cardio:ct-nct01870804
Content hash
472f58b03134dd6b597424b483d2f6c202e19ffb4e2b4df4d5e6891b099ab9d3